Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin
| Autor: | Sara Feola, Manlio Fusciello, Beatriz Martins, Erkko Ylösmäki, Vincenzo Cerullo, Tapani Viitala, Firas Hamdan, Jacopo Chiaro, Leena Ylösmäki, Matthew J Vaughan, Prasad S Kulkarni |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2021-0027 2051-1426 |
| DOI: | 10.1136/jitc-2021-002707 |
| Popis: | Background Intratumoral BCG therapy, one of the earliest immunotherapies, can lead to infiltration of immune cells into a treated tumor. However, an increase in the number of BCG-induced tumor-specific T cells in the tumor microenvironment could lead to enhanced therapeutic effects.Methods Here, we have developed a novel cancer vaccine platform based on BCG that can broaden BCG-induced immune responses to include tumor antigens. By physically attaching tumor-specific peptides onto the mycobacterial outer membrane, we were able to induce strong systemic and intratumoral T cell-specific immune responses toward the attached tumor antigens. These therapeutic peptides can be efficiently attached to the mycobacterial outer membrane using a poly-lysine sequence N-terminally fused to the tumor-specific peptides.Results Using two mouse models of melanoma and a mouse model of colorectal cancer, we observed that the antitumor immune responses of BCG could be improved by coating the BCG with tumor-specific peptides. In addition, by combining this novel cancer vaccine platform with anti-programmed death 1 (anti-PD-1) immune checkpoint inhibitor (ICI) therapy, the number of responders to anti-PD-1 immunotherapy was markedly increased.Conclusions This study shows that intratumoral BCG immunotherapy can be improved by coating the bacteria with modified tumor-specific peptides. In addition, this improved BCG immunotherapy can be combined with ICI therapy to obtain enhanced tumor growth control. These results warrant clinical testing of this novel cancer vaccine platform. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|